Section of Endocrinology and Metabolism, University of Siena, Siena, Italy.
J Endocrinol Invest. 2012;35(6 Suppl):36-9.
Differentiated thyroid carcinoma (DTC), either papillary or follicular, has usually a very good prognosis with an overall mortality of less than 10%. In recent decades, the clinical presentation of DTC has been changing from advanced cases requiring intense treatment and surveillance to cancer detected by fortuitous neck ultrasonography requiring less aggressive treatment and follow-up. Given the changing presentation of DTC in the last years, the aim of DTC follow-up is to ensure the most effective and less invasive follow-up for a disease that nowadays is mostly cured just with surgery and is rarely fatal. The concept of "Ongoing Risk Stratification" or "Delayed Risk Stratification" which better define the patient risk based on the results of the initial treatment, can maximize the beneficial effects of aggressive therapy in patients with DTC who are likely to benefit from it, while minimizing potential complications and side effects in low-risk patients who will achieve complete remission.
分化型甲状腺癌（DTC），无论是乳头状还是滤泡状，通常具有非常好的预后，总体死亡率低于 10%。在最近几十年，DTC 的临床表现已经从需要强化治疗和监测的晚期病例转变为偶然通过颈部超声检查发现的癌症，这些癌症需要的治疗和随访不那么激进。鉴于 DTC 在过去几年中的表现变化，DTC 随访的目的是确保对这种疾病进行最有效和侵袭性最小的随访，因为现在这种疾病主要通过手术治愈，很少致命。“持续风险分层”或“延迟风险分层”的概念，根据初始治疗的结果更好地定义患者的风险，可以使那些可能从中受益的 DTC 患者的强化治疗的有益效果最大化，同时使那些有望完全缓解的低危患者的潜在并发症和副作用最小化。
